Figure 1 | Scientific Reports

Figure 1

From: TAS0314, a novel multi-epitope long peptide vaccine, showed synergistic antitumor immunity with PD-1/PD-L1 blockade in HLA-A*2402 mice

Figure 1

CTL induction by TAS0314 vaccination in various HLA-KI mice. Mice (n = 10) were treated with TAS0314 (300 μg/each peptide) once a week. One week after the last immunization, draining lymph node cells were isolated, and pooled lymphocytes were cultured for 8 days with epitope peptide, IL-15, and IL-21. Epitope-specific CTLs were evaluated with an IFN-γ ELISPOT assay (four wells/peptide). (a) HLA-A24-restricted epitope-specific CTL induction in HLA-A*2402 KI mice. (b) HLA-A2-restricted epitope-specific CTL induction in HLA-A*0201 KI mice. (c) HLA-A3 superfamily-restricted epitope-specific CTL induction in HLA-A*3101 KI mice. Data represent the mean ± standard deviation (n = 4). *p < 0.05 using a two-tailed Student’s t test.

Back to article page